Losartan reduces aortic dilatation rate in adults with Marfan syndrome: A randomized controlled trial

European Heart Journal

Volumn 34, Issue 45, 2013, Pages 3491-3500

  Groenink, Maarten ^a,b   Den Hartog, Alexander W ^a,b   Franken, Romy ^a,b   Radonic, Teodora ^a   De Waard, Vivian ^a   Timmermans, Janneke ^c   Scholte, Arthur J ^d   Van Den Berg, Maarten P ^e   Spijkerboer, Anje M ^a   Marquering, Henk A ^a   Zwinderman, Aeilko H ^a   Mulder, Barbara J M ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Aortic dilatation rate; Aortic root; Losartan; Magnetic resonance imaging; Marfan syndrome

Indexed keywords

LOSARTAN;

ADULT; AORTA DILATATION; AORTA DISEASE; AORTA DISSECTION; AORTA ROOT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AORTIC DILATATION RATE; AORTIC ROOT; LOSARTAN; MAGNETIC RESONANCE IMAGING; MARFAN SYNDROME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTA, THORACIC; AORTIC DISEASES; DILATATION, PATHOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOSARTAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MARFAN SYNDROME; REOPERATION; TREATMENT OUTCOME;

EID: 84888237597     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht334     Document Type: Article

References (34)

1. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol 1995;75:157-160.
2. Engelfriet P, Mulder B. Is there benefit of beta-blocking agents in the treatment of patients with the Marfan syndrome? Int J Cardiol 2007;114:300-302.
3. Hartog AW, Franken R, Zwinderman AH, Groenink M, Mulder BJ. Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin Pharmacother 2012;13:647-662.
4. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-Term beta-Adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-1341.
5. Cameron DE, Alejo DE, Patel ND, Nwakanma LU,Weiss ES, Vricella LA, Dietz HC, Spevak PJ, Williams JA, Bethea BT, Fitton TP, Gott VL. Aortic root replacement in 372 Marfan patients: evolution of operative repair over 30 years. Ann Thorac Surg 2009;87:1344-1349.
6. Engelfriet PM, Boersma E, Tijssen JG, Bouma BJ, Mulder BJ. Beyond the root: dilatation of the distal aorta in Marfan's syndrome. Heart 2006;92:1238-1243.
7. Groenink M, Lohuis TA, Tijssen JG, Naeff MS, Hennekam RC, Van Der Wall EE, Mulder BJ. Survival and complication free survival in Marfan's syndrome: implications of current guidelines. Heart 1999;82:499-504.
8. Robinson PN, Arteaga-Solis E, Baldock C, Collod-Beroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006;43:769-787.
9. Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 2007;17:252-258.
10. Franken R, den Hartog AW, de Waard V, Engele L, Radonic T, Lutter R, Timmermans J, Scholte AJ, van den Berg MP, Zwinderman AH, Groenink M, Mulder BJ. Circulating transforming growth factor-beta as a prognostic biomarker in Marfan syndrome. Int J Cardiol; doi: 10.1016/j.ijcard.2013.03.033. Published online ahead of print 10 April 2013.
11. Carlson RG, LilleheiCW, Edwards JE. Cystic medial necrosis of the ascending aorta in relation to age and hypertension. Am J Cardiol 1970;25:411-415.
12. Nagashima H, Sakomura Y, Aoka Y, Uto K, Kameyama K, Ogawa M, Aomi S, Koyanagi H, Ishizuka N, Naruse M, Kawana M, Kasanuki H. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 2001;104(12 Suppl. 1): I282-I287.
13. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, anAT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312: 117-121.
14. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.
15. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-365.
16. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, DietzHCIII. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358: 2787-2795.
17. Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials 2010;11:3.
18. van der Velde ET, Vriend JW, Mannens MM, Uiterwaal CS, Brand R, Mulder BJ. CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results. Eur J Epidemiol 2005;20:549-557.
19. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-426.
20. Baumgartner H, Bonhoeffer P, De Groot NM, de HF, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-2957.
21. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;121:e266-e369.
22. Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993;22: 1470-1476.
23. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 2001;322: 1479-1480.
24. Vasan RS, Larson MG, Levy D. Determinants of echocardiographic aortic root size. The Framingham Heart Study. Circulation 1995;91:734-740.
25. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004;114:172-181.
26. Radonic T, de Witte P, Groenink M, de Waard V, Lutter R, van Eijk M, Jansen M, Timmermans J, Kempers M, Scholte AJ, Hilhorst-Hofstee Y, van den Berg MP, van Tintelen JP, Pals G, Baars MJ, Mulder BJ, Zwinderman AH. Inflammation aggravates disease severity in Marfan syndrome patients. PLoS One 2012;7:e32963.
27. Meijboom LJ, Groenink M, Van DerWall EE, Romkes H, Stoker J, Mulder BJ. Aortic root asymmetry in marfan patients; evaluation by magnetic resonance imaging and comparison with standard echocardiography. Int J Card Imaging 2000;16:161-168.
28. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869.
29. Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta. Dev Biol 1996; 178:430-445.
30. Mulder BJ. The distal aorta in the Marfan syndrome. Neth Heart J 2008;16:382-386.
31. Nollen GJ, Meijboom LJ, Groenink M, Timmermans J, Barentsz JO, Merchant N, Webb GD, Lamb HJ, Tijssen JG, Van Der Wall EE, Mulder BJ. Comparison of aortic elasticity in patients with the Marfan syndrome with and without aortic root replacement. Am J Cardiol 2003;91:637-640.
32. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ. Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 2005;96: 1441-1444.
33. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, RomanMJ, Seward J, Shanewise JS, Solomon SD, SpencerKT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
34. den Hartog AW, Franken R, de Witte P, Radonic T, Marquering HA, van der Steen WE, Timmermans J, Scholte AJ, van den Berg MP, Zwinderman AH, Mulder BJ, Groenink M. Aortic disease in patients with Marfan syndrome: Aortic volume assessment for surveillance. Radiology; doi: 10.1148/radiol.13122310. Published online ahead of print 25 June 2013.